Treatment of base excision repair-proficient mouse fibroblasts with the DNA alkylating agent methyl methanesulfonate (MMS) and a small molecule inhibitor of PARP-1 results in a striking cell killing phenotype, as previously reported. Earlier studies showed that the mechanism of cell death is apoptosis and requires DNA replication, expression of PARP-1, and an intact S-phase checkpoint cell signaling system. It is proposed that activity-inhibited PARP-1 becomes immobilized at DNA repair intermediates, and that this blocks DNA repair and interferes with DNA replication, eventually promoting an S-phase checkpoint and G 2 -M block. Here we report studies designed to evaluate the prediction that inhibited PARP-1 remains DNA associated in cells undergoing repair of alkylation-induced damage. Using chromatin immunoprecipitation with anti-PARP-1 antibody and qPCR for DNA quantification, a higher level of DNA was found associated with PARP-1 in cells treated with MMS plus PARP inhibitor than in cells without inhibitor treatment. These results have implications for explaining the extreme hypersensitivity phenotype after combination treatment with MMS and a PARP inhibitor. Mol Cancer Res; 10(3); 360-8. Ó2012 AACR.
Introduction
PARP-1 plays a central and multifaceted role in the array of cellular responses to DNA damage. In the case of the base excision DNA repair (BER) pathway, PARP-1 is considered to be a member of the first group of DNA repair-associated proteins to recognize and bind at the DNA lesion or an initial intermediate of repair (e.g., abasic site or strand break; refs. [1] [2] [3] [4] [5] [6] . Upon binding to a BER strand break-containing intermediate, PARP-1 is activated for synthesis of PAR and is considered to function as an accessory factor in recruiting and stabilizing the repair complex (2, 7, 8) . PARP-1 undergoes automodification with PAR (PARylation) and also PARylates other repair proteins. After auto-PARylation, PARP-1 is proposed to dissociate from DNA (9) , yet the precise roles of PARP-1 and PARylation in BER are still obscure and under investigation. Nevertheless, BER is partially blocked when PARP activity is inhibited by treatment of cells with a small molecule inhibitor (7, 10, 11) . Despite these observations, repair-proficient cells in culture experiencing endogenous DNA base damage are resistant to PARP inhibitors, presumably because alternative DNA repair pathways can compensate for a block in BER (12) (13) (14) . In contrast, when double-strand break (DSB) repair by homologous recombination or nonhomologous end joining is deficient in cells, they become sensitive to PARP inhibitors (15) . In light of this background information, PARP inhibitors are being widely explored in therapeutic approaches for tumors with DSB repair deficiencies (12, 16) .
It is important to gain a deeper understanding of cellular mechanisms that will inform cancer therapeutic approaches involving PARP inhibitors. One approach has been the study of cytotoxicity in human and mouse fibroblasts as a function of DNA repair and PARP inhibition. Even wild-type mouse fibroblasts are extremely sensitive to treatment with combinations of PARP inhibitors and alkylating agents that trigger the BER pathway. For example, a low, sublethal dose of methyl methanesulfonate (MMS) combined with the PARP inhibitor 4-amino-1,8-naphthalimide (4-AN) results in greater than 99% cell killing after several days of culture (17, 18) . This extreme cytotoxicity occurs mainly through apoptotic cell death, requires treatment in replicating cells, and involves activation of components of the S-phase cellcycle checkpoint system (18, 19) . The effects of treatment with the PARP inhibitor plus alkylating agent combination (MMS þ 4-AN) include accumulation of DNA DSBs, as measured by pulsed field gel electrophoresis and immunostaining for phosphorylated histone H2A.X (20, 21) . Interestingly, PARP-1 À/À mouse cells are only mildly sensitive to the MMS þ 4-AN combination compared with wild-type cells (17) and failed to accumulate DSBs after treatment (20) . These results suggested that in wild-type cells, the inhibited PARP-1 protein itself plays a role in the apoptotic cell killing phenotype, as the loss of PARP-1 did not produce the same effect as inhibiting PARP (18) .
In human and mouse fibroblasts, the S-phase checkpoint observed following treatment with the MMS þ 4-AN combination resulted in activation of ATR and the ATR effector kinase Chk1 (22) . ATM was implicated in the checkpoint response also, and loss of either ATM or of its downstream effector kinase, Chk2, limited the S-phase delay (23) . The S-phase checkpoint also required NBS1 phosphorylation by ATR, while NBS1 modulated ATM in its response to the combination treatment. NBS1 modulated activation of SMC1, a downstream effector in an alternate S-phase checkpoint mechanism (19) .
A working model ( Fig. 1) for the observed effects following treatment with the MMS þ 4-AN combination is as follows: (i) A DNA alkylating agent triggers BER and intermediates with an APE1-incised AP site are generated. These BER intermediates, containing 5 0 -deoxyribose phosphate (dRP), are bound by the abundant PARP-1 protein in its DNA damage response; (ii) Under normal conditions, in the absence of PARP inhibition (Fig. 1, left) , there is significant PARylation of PARP-1, BER factors are recruited to the BER intermediate, and BER proceeds to completion along with release of PARylated PARP-1 from the DNA. When PARP activity is inhibited by 4-AN (Fig. 1, right) , PARP-1 becomes frozen at the BER intermediates blocking BER; (iii) DNA replication forks collide with the BER intermediate/inhibited PARP-1 complex and stall. Subsequently, the cell signaling system triggers an S-phase checkpoint, accumulation of cells in G 2 -M, accumulation of DSBs and cell death by apoptosis.
Although Fig. 1 is consistent with results obtained so far, key information is still lacking at most of the steps, and alternate models for explaining cell sensitivity to PARP inhibitors are possible. Therefore, it is important to further examine the model in Fig. 1 , along with other models (24, 25) , to gain a better understanding of the cytotoxic responses to PARP inhibition during BER in replicating cells (26, 27) .
In this study, we examined a prediction of the model in Fig. 1 about the mechanism of cytotoxicity after the MMS þ 4-AN treatment. The prediction is that upon treatment with this combination, more genomic DNA could be found in association with PARP-1 than in cells treated with MMS alone or in control, untreated cells. We tested this prediction using a chromatin immunoprecipitation (ChIP) procedure with anti-PARP-1 antibody followed by quantification of DNA in the immunoprecipitated samples. The results are discussed in relation to the model in Fig. 1 .
Materials and Methods

Materials
Dulbecco's modified Eagle's medium (DMEM), FBS, and Hank's balanced salt solution (HBSS) were from HyClone. GlutaMAX-1 and hygromycin B were from Invitrogen. MMS and the PARP inhibitor (4-AN) were from SigmaAldrich. Restore Western Blot Stripping Buffer and SuperSignal West Pico Chemiluminescent substrate were from Thermo Scientific. Western Lightning Plus-ECL Enhanced 
Methods
Cell culture and synchronization. The wild-type mouse embryonic fibroblasts (MB16.3) have been described (28) . Cells were routinely grown at 34 C in a 10% CO 2 incubator in DMEM supplemented with GlutaMAX-1, 10% FBS, and hygromycin (80 mg/mL). All cells were routinely tested and found to be free of Mycoplasma contamination. Cell synchronization was as described (17) . Briefly, cells were seeded at a cell density of 8 Â 10 6 cells per 145-mm dish and the following day were washed once with HBSS and once with DMEM containing 0.2% FBS. Then the cells were incubated with DMEM containing 0.2% FBS for 48 hours. The medium was then removed and the cells were incubated with 2.5 mmol/L APH in DMEM with 10% FBS for 16 hours. The noncycling cells were washed with HBSS, and drug-free 10% FBS-containing DMEM was added. Culture was continued for 4 hours to allow cell cycling to resume.
ChIP. For the ChIP assay, synchronized cells in 145-mm dishes were subjected to cell treatment protocols as follows. For MMS alone, MMS was added directly to the medium to a final concentration of 0.25 mmol/L, and after 1 hour, the cells were washed with HBSS. Fresh medium was added, and culture was continued for 1 hour. For 4-AN alone, 4-AN was added directly to the medium to a final concentration of 10 mmol/L, and culture was continued for 2 hours. For combination treatment with MMS þ 4-AN, both MMS and 4-AN were added to final concentrations of 0.25 mmol/L and 10 mmol/L, respectively. After 1 hour, the medium was removed and fresh medium with 10 mmol/L 4-AN was added. Culture was then continued for 1 hour. Synchronized cells referred to as "control" were mock treated and cultured at each step, but with drug-free medium.
The ChIP procedure involved an in vivo protein/DNA cross-linking treatment of cells with formaldehyde, nuclei preparation, micrococcal nuclease digestion of chromatin, and then immunoprecipitation. ChIP was done with the Chromatin IP Kit, described above, using 5 dishes of cultured cells. Briefly, cells were grown to approximately 80% to 90% confluence, cross-linked with 1% formaldehyde in medium for 10 minutes at room temperature, and then the medium was adjusted to 125 mmol/L glycine. The cells then were held for 5 minutes at room temperature, to quench the formaldehyde cross-linking. The cells were washed twice with PBS at 4 C. Finally, 2 mL PBS containing 5 mmol/L PMSF at 4 C was added to each dish. Cells were scraped, and cells from the 5 dishes were combined into a 15-mL conical tube. The cells were pelleted by centrifugation, then resuspended in 10 mL Buffer A (provided by the manufacturer) at 4 C and held at 4 C for 10 minutes. Nuclei were obtained by centrifugation, and the nuclear pellets were resuspended in 10 mL Buffer B (provided by the manufacturer) at 4 C. The suspension was digested with 5 mL of micrococcal nuclease (2,000 gel units/mL) with incubation at 37 C for 20 minutes. The nuclease reaction was stopped by adding EDTA and placing the mixture at 4 C. Nuclei were then collected by centrifugation. Nuclear pellets were resuspended in 1ÂChIP Buffer (provided by the manufacturer). Each tube was sonicated with several pulses with a Sonic Dismembrator; the samples were held for 30 seconds in wet ice between pulses. The lysate, that is the chromatin preparation, was clarified by centrifugation, divided into aliquots, and stored at À80 C. The chromatin preparations from cells treated with the MMS þ 4-AN combination, MMS or 4-AN alone, and control were used in immunoprecipitation incubations. For each chromatin preparation, the sample was thawed and diluted to 400 mL with 1 Â ChIP Buffer containing protease inhibitor cocktail (provided by the manufacturer). A portion corresponding to 2% of the diluted chromatin preparation from each cell treatment was transferred to a microfuge tube and stored at À20 C. Next, the samples were thawed and mixed with either monoclonal antibody (mAb) against PARP-1, mAb against histone H3 (as a positive control), or nonimmune normal rabbit IgG (as a negative control). After overnight incubation at 4 C, ChIP-grade protein G-agarose beads were added, and the mixture was incubated for 4 hours at 4 C. The beads were collected by centrifugation and washed with 1 Â ChIP Buffer. The precipitated proteins were digested by proteinase K treatment, and DNA was obtained according to the manufacturer. Real-time quantitative PCR (qPCR) was used to measure the DNA content of the immunoprecipitated material. As a positive control for the DNA quantification, ChIP samples were prepared from each type of cell treatment with anti-histone H3 antibody.
Real-time quantitative PCR analysis of DNA in the ChIP samples. The PCR program was set up in the ABI Prism SDS 2.1 (with 7900 HT Sequence detection system). The PCR reaction was conducted in a 96-well clear plate with a final reaction volume of 25 mL containing 12.5 mL of Power SYBR Green Master mix, 10 mmol/L each of forward and reverse isochore primers (described below), and 1.5 mL of DNA extracted from the ChIP sample; the final volume was made up to 25 mL with water. Each reaction mixture was set up in triplicate. The cycling conditions comprised 50 C for 2 minutes (1 cycle), 95 C for 10 minutes (1 cycle), and 40 cycles of 95 C for 15 seconds and 60 C for 1 minutes. The amount of immunoprecipitated DNA in each sample was determined relative to input chromatin DNA. Each ChIP experiment was conducted a minimum of 3 times with independent chromatin isolates. ChIP samples prepared with histone H3 antibody served as a positive control and DNA was quantified with isochore primers. A similar amount of DNA was found in these anti-histone H3 ChIP samples isolated after the different types of cell treatment (data not shown).
For quantification of DNA by qPCR, we first chose primers targeted for GC-rich isochores (29) (30) (31) (32) . Many different primer sets were surveyed, but most were found to be problematic, including a line sequence NCBI: NM_013627 and isochore primer NCBI: NM_018779. However, the isochore primer set NCBI: NM_019426 gave excellent results and was used in the DNA quantification experiments. Sequence information on this mouse oligonucleotide isochore primer set is described in NCBI, Ref. Before use in real-time qPCR experiments, these primers were analyzed for efficiency using the thermocycler.
Analysis of PARP-1 protein in the ChIP samples. For the analysis of PARP-1 in the ChIP samples, the cross-linked immunoprecipitated samples were not digested with proteinase K but, instead, were subjected to a treatment protocol to reverse the cross-linking before analysis on SDS-PAGE gels. The washed beads containing the ChIP sample were suspended in 1Â ChIP Buffer. The mixture was adjusted to 200 mmol/L NaCl and incubated for 2 hours at 65 C. The mixture was combined with SDS-PAGE gel loading solution and heated at 95 C for 6 minutes. The mixture was centrifuged and the supernatant fraction was loaded onto a 4% to 12% gradient gel. In some experiments, the gel was subjected to analysis by mass spectrometry (33) , and in others proteins, were transferred to a nitrocellulose membrane, and the membrane was probed with anti-PARP-1 mouse mAb and G3PDH as a loading control (34) . Purified PARP-1, used as a positive control, was prepared as described (35) .
Mass spectrometry verification of PARP-1 in anti-PARP-1 ChIP samples. Whole lanes from a polyacrylamide gel were digested using a Progest robotic digester (Genomic Solutions), in which each lane was cut into 24 slices. These slices were incubated twice for 15 minutes in 100 mL of 50:50 (v:v) 25 mmol/L ammonium bicarbonate: acetonitrile. The gel was then dehydrated by incubating for 20 minutes in 100 mL of acetonitrile followed by drying under a nitrogen stream for 18 seconds. Trypsin (250 ng; Promega) was added and the gel pieces incubated for 12 hours at 37 C. The supernatant solutions from the digests were saved and combined with the supernatants from reextractions. The gels were reextracted 3 times: once with 50 mL of water for 20 minutes and twice with 20-minute incubations in 50 mL of 45:50:5 (v:v:v) water:acetonitrile: formic acid. The pooled supernatants were lyophilized and resuspended in 40 mL of 0.1% formic acid.
NanoLC-ESI-MS-MS (electrospray-tandem mass spectrometry) analyses were done using an Agilent 1200 nanoLC system on-line with an Agilent 6340 ion trap mass spectrometer with the chip cube interface. Buffer A was 99.9:0.1 (v:v) water:formic acid and buffer B was 99.9:0.1 (v:v) acetonitrile:formic acid. Briefly, 20 mL of the peptide digest was loaded onto an Agilent ProtID chip (75 mm Â 43 mm) followed by a 15-minute wash with 95% A, 5% B. Peptides were eluted with a linearly increasing gradient of buffer B as follows: 0 to 45 minutes, 5% to 50% B, 45 to 50 minutes, B increased to 95%, 50 to 60 minutes maintained at 95% B. The mass spectrometer was used in the positive ion, standard enhanced mode and included settings of a mass range from 200 to 2,200 m/z, an ionization potential of 1.9 kV, an ICC smart target (number of ions in the trap prior to scan out) of 200,000 or 200 ms of accumulation, and a 1.0-V fragmentation amplitude. MS-MS data were acquired using a datadependent acquisition format with the 6 most abundant ions from each MS scan further interrogated by MS-MS. The automated switching for MS-MS required a threshold of 10,000 counts.
Peak lists were generated from the data obtained from each nanoLC-ESI-MS-MS analysis using the data extractor feature of the Spectrum Mill MS Proteomics Workbench from Agilent. The data extractor settings included limiting the data search to ions observed between 300 and 5,000 Da and a retention time between 10 and 55 minutes. MS scans with the same precursor mass (AE1.5 m/z) and retention time within 30 seconds were merged. In addition, of the remaining MS-MS spectra, only spectra that contained sequence tag information greater than 2 residues were submitted for database searching. The resulting extracted data were searched against the human and rodent limited International Protein Index database (IPI_human_rodent) using the MS-MS Search function in the Spectrum Mill software. Search settings included a trypsin specificity with up to a single missed cleavage allowed, a precursor ion mass tolerance of 1.5 Da, a product ion mass tolerance of 1.0 Da, variable methionine oxidation, and a minimum matched spectral intensity of 80%. PARP-1 peptides found in the ChIP samples are summarized in Table 1 .
Analysis of PARP-1 in the chromatin-associated and nuclear soluble protein fractions. The isolation of the nuclear fraction and the separation of soluble and chromatinassociated nuclear proteins were based on the protocol described by Mendez and Stillman (36) , with modifications from Ritzi and colleagues (37) . To inhibit proteases, all buffers were supplemented with 25 mmol/L MG-132; a 10 mmol/L stock solution was prepared in dimethyl sulfoxide. Cells in one 145-mm dish were synchronized and treated as described above. Cells were then harvested, washed with PBS, and resuspended in 250 mL hypotonic buffer A [10 mmol/L HEPES, pH 7.9, 10 mmol/L KCl, 1.5 mmol/L MgCl 2 , 0.34 mol/L sucrose, 10% glycerol, 1 mmol/L DTT, and protease inhibitor mix Complete (according to the manufacturer)]. Next, for cell lysis, the suspension was adjusted to 0.1% Triton X-100 and incubated for 5 minutes at 4 C. The nuclei were separated by centrifugation at 1,300 Â g for 4 minutes at 4 C and washed once with buffer A. The nuclei were then lysed by suspension in low stringency solution (3 mmol/L EDTA, 0.2 mmol/L EGTA, 1 mmol/L DTT) for 10 minutes at 4 C. The insoluble chromatin fraction and the nuclear soluble protein fraction were separated by centrifugation at 1,700 Â g for 4 minutes, and the pelleted chromatin fraction was washed once with low-stringency solution. This final pellet fraction was used to assess the chromatin-associated proteins. These proteins were extracted by addition of 250 mL buffer (50 mmol/L Tris-HCl, pH 8.0, 150 mmol/L NaCl, 0.1% SDS, 0.5% sodium deoxycholate, and 1% NP40) at 4 C and incubation for 30 minutes at 4 C. The mixture was centrifuged at 16,000 Â g for 10 minutes at 4 C. The supernatant fraction (extract) was removed, and the protein concentration was measured using the Bio-Rad protein assay with BSA as standard. Equal "cell equivalents" of nuclear soluble protein fraction and chromatin-associated protein fraction were analyzed by immunoblotting for PARP-1 and histone H3 or Lamin A, as a control (ref. 38; see Fig. 4A ). The amount of PARP-1 in the chromatin-associated protein fraction also was analyzed by immunoblotting as described above (see Fig. 4B and C) .
Results
We explored a prediction of the model in Fig. 1 . Briefly, when BER occurs in a replicating cell, PARP inhibition will cause PARP-1 to freeze at BER intermediates, and eventually a replication fork will collide with the inhibited PARP-1/ DNA complex. Replication fork progression will stall, leading to S-phase checkpoint signaling and DSBs. The prediction to be tested is that more DNA will be found in association with PARP-1 when cells are treated with the MMS þ 4-AN combination than when cells are untreated.
For evaluating this prediction, we used the ChIP procedure with anti-PARP-1 antibody. After in vivo cross-linking of DNA-protein complexes and antibody pull-down, the cross-linking was reversed and genomic DNA in the samples was quantified by real-time qPCR using isochore primers for amplification of general genomic DNA. Mouse fibroblasts that had been synchronized in S-phase were used and the treatment protocol is summarized in Fig. 2A . Cells treated with MMS alone or 4-AN alone were prepared along with control (mock treated) cells and cells treated with the MMS þ 4-AN combination. In each case, the same number of cells was subjected to the cross-linking and ChIP procedure. In initial experiments, to rule out any differences in PARP-1 level in these cells, we quantified PARP-1 expression in the various cell extracts by immunoblotting. The amount of PARP-1 protein was similar in the control and 3 types of treated cells (Fig. 2B , upper panel) using G3PDH as a loading control (bottom panel). In addition, we verified that PARP-1 had been immunoprecipitated in our ChIP samples, and this was accomplished using mass spectrometric analysis. In each case in which the ChIP procedure included anti-PARP-1 antibody, the presence of PARP-1 in the immunoprecipitate was verified (Table 1) . ChIP samples prepared with the control nonimmune IgG failed to yield significant PARP-1 ( Table 1) .
Results of DNA quantification with the anti-PARP-1 ChIP samples are shown in Fig. 3 . Considerably increased levels (>10-fold) of DNA were found in samples prepared from MMS þ 4-AN-treated cells than from the control cells. With cells treated either with MMS or 4-AN alone, there were increases in DNA associated with PARP-1, but these were considerably less than with the MMS þ 4-AN combination. Next, we designed confirmatory experiments with PCR primers other than the isochore primers used in the experiments in Fig. 3A . The DNA quantification of the ChIP samples was conducted using primers against an expressed gene (pol b). The results with independently prepared ChIP samples are shown in Fig. 3B . Again, increased levels of DNA were found in association with PARP-1 in the samples from MMS þ 4-AN-treated cells compared with control cells. In contrast to the results with isochore primers, samples from cell treated either with MMS or 4-AN alone had significantly less DNA associated with PARP-1. We conclude from the experiments in Fig. 3 that more genomic DNA was associated with PARP-1 in the MMS þ 4-AN-treated cells than in the control or single agent-treated cells. Thus, our initial prediction was confirmed.
In view of the results shown in Fig. 3 , indicating increased DNA in association with PARP-1 in the MMS þ 4-ANtreated cells, we were curious to know whether these cells also contained more chromatin-associated PARP-1 than cells subjected to the other treatments studied here, that is, control, MMS treated, and 4-AN treated. Control and the 3 types of treated cells were prepared as described in Fig. 2A and nuclei were isolated. The nuclei were then separated into a nuclear soluble fraction and a chromatin-associated fraction, and the amount of PARP-1 in each was quantified by immunoblotting. For the control cells and all cell treatments, the amount of PARP-1 in the chromatin-associated fraction was greater than in the nuclear soluble fraction (Fig. 4A ). In the sample from MMS þ 4-AN-treated cells, there was a modest increase in the ratio of chromatin-associated PARP-1 versus nuclear soluble fraction PARP-1 (compare lanes 4 and 8, Fig. 4A ). Yet, there was no difference in the amount of chromatin-associated PARP-1 as a function of cell treatment (Fig. 4A ). This was confirmed in an immunoblotting Figure 3 . DNA associated with PARP in ChIP samples from control and treated cells. Experiments were conducted as described under Methods. DNA was purified from the various ChIP samples and measured by qPCR using (A) isochore primers and (B) pol b primers. The amount of DNA in each type of ChIP sample is represented as the qPCR signal relative to a constant amount of input chromatin DNA. The data represent average values (with SD bars) from 3 independent ChIP samples, each one measured in triplicate. In A and B, the triple asterisk symbols indicate difference from the respective control samples at P < 0.001 using the 2-sample t test, and in B, the single asterisk symbols indicate difference from the control samples at P < 0.05 using the 2-sample t test. The results with the MMS þ 4-AN samples in A and B are different from all other samples at P < 0.001 using the 2-sample t test.
quantification experiment of chromatin-associated PARP-1, using increasing amounts of chromatin-associated fraction from the control and MMS þ 4-AN-treated cells (Fig. 4B) . Interestingly, the results revealed no difference in the amount of chromatin-associated PARP-1, as a function of the combination treatment (Fig. 4C) .
Finally, another prediction of the model in Fig. 1 is that Sphase checkpoint signaling is associated with the inhibited PARP-1-DNA complex. It is known that an S-phase checkpoint response occurs in these MMS þ 4-AN-treated cells (22) and that this involves phosphorylation of ATR and NBS1, as well as other cell signaling proteins (19) . We asked whether the ChIP sample with anti-PARP-1 antibody also contained ATR, NBS1, and related factors, such as RPA70 and MRE11. The results of immunoblotting analysis of the ChIP samples prepared with anti-PARP-1 antibody and control IgG are shown in Fig. 5 . PARP-1 was present, as expected, and NBS1, MRE11, RPA70, and ATR also were detected. These results were consistent with the prediction that a protein-DNA complex containing inhibited PARP-1 is in close proximity to these S-phase checkpoint response factors.
Discussion
In vivo cross-linking and ChIP analysis has been widely used to identify DNA sequence elements associated with a protein of interest. In the experiments described here, the method was used to measure general genomic DNA associated with the PARP-1 protein. The relative amount of DNA in association with PARP-1 was found to be greater in PARP inhibitor-treated cells undergoing MMS-induced repair than in cells without MMS treatment or without inhibitor treatment (Fig. 3) . These results are consistent with a prediction from the working model in Fig. 1 and represent the first direct measurements of DNA-associated PARP-1 as a function of inhibitor treatment. In addition, S-phase checkpoint response factors were found to coimmunoprecipitate in the anti-PARP-1 ChIP samples. This finding is also consistent with a prediction of the model in Fig. 1 and suggests that these response factors are in proximity to PARP-1 in the MMS þ 4-AN-treated cells.
The model in Fig. 1 resembles models proposed by others (7, 39, 40) and also is in line with an original proposal on DNA association of inhibited PARP-1 by Satoh and Lindahl (9). As summarized above, accumulation of DSBs in mouse fibroblasts cells treated with the MMS þ 4-AN combination had been shown earlier (20) , and these cells exhibited single-strand DNA-mediated and DSB-mediated cell-cycle checkpoint signaling (22, 23 ). Yet, these results are also consistent with other models in which PARP-1 becomes DNA-associated and is frozen in complex with DNA upon inhibition, and different models explaining the cytotoxicity of PARP inhibitors and DNA damaging agents have been discussed by others (15, 24, 41) .
PARP-1 is abundantly expressed in mouse fibroblasts and almost all of it is found in nuclei (Prasad and colleagues; unpublished observations). The results presented here on quantification of the cellular level of PARP-1 as a function of MMS þ 4-AN treatment indicated that the PARP-1 protein level did not fluctuate as a function of the treatments (Fig.  2B) . Much of the nuclear PARP-1 was found in the chromatin-associated fraction, as opposed to the nuclear soluble fraction, and this picture failed to change significantly with the various cell treatments (Fig. 4A) . Similarly, in the chromatin immunoprecipitates with anti-PARP-1 antibody, the amount of PARP-1 immunoprecipitated did not change as a function of the cell treatments. In contrast, the amount of DNA associated with PARP-1 in the MMS þ 4-AN-treated cells was greater than that for the other treatments (Fig. 3) . Thus, a larger portion of the chromatinbound PARP-1 was associated with DNA and found crosslinked by the ChIP procedure. The lower level of PARP-1-DNA complex found in control cells implies that PARP-1 is bound to chromatin proteins rather than the DNA.
Finally, with regard to therapeutic approaches with PARP inhibitors, it may be interesting to test strategies for inhibiting additional factors in the BER pathway (42, 43) . A phenomenon of increased cytotoxicity of this type has already been observed in mouse fibroblasts that are deficient in pol b (8) or XRCC1 (10) . Thus, inhibition of an enzyme in BER, in addition to PARP-1, may enhance accumulation of BER intermediates and consequently provide more sites for trapping inhibited PARP-1. Increased cytotoxicity would be anticipated with the combination of a BER enzyme deficiency and a PARP inhibitor while triggering BER. Hence, strategies for increasing the cytotoxicity of combination treatment with alkylating agents and PARP inhibitors may include small molecule inhibitors against the BER enzymes and cofactors, including AP endonuclease 1, pol b, polynucleotide kinase, tyrosyl-DNA phosphodiesterase, aprataxin, DNA ligases, and XRCC1. Similarly, genetic deficiencies in these BER factors in tumor cells may render them hypersensitive to combination treatment (42) .
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